To include your compound in the COVID-19 Resource Center, submit it here.

ImmunoGen seals ADC deal with Jazz

ImmunoGen Inc. (NASDAQ:IMGN) granted Jazz Pharmaceuticals plc (NASDAQ:JAZZ) an exclusive option to develop and commercialize three of ImmunoGen's antibody-drug conjugate (ADC) programs.

Jazz will pay ImmunoGen $75 million up front

Read the full 297 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE